3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Genitourinary
1
Conditions
Prostatic Neoplasms
7
Carcinoma, Renal Cell
3
Urologic Diseases
1
Resectable Localized Prostate Cancer
1
Prostate Cancer Recurrent
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Nephritis
1
Melanoma
1
Lung Neoplasms
1
Kidney Diseases
1
Immune System Diseases
1
Glomerulonephritis, IGA
1
Glomerulonephritis
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Autoimmune Diseases
1
Adenocarcinoma of Lung
1
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
testosterone undecanoate
1
tempol
1
TEMPOL-H
1
Sirolimus
1
Nelfinavir
1
Metformin
1
Hydroxychloroquine
1
Gonadotropins
1
Diet, Protein-Restricted
1
Dasatinib
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostate Cancer Recurrent
×
Hydroxychloroquine
×
Genitourinary
×
Clear all
NCT05036226
2026-05-13
COAST
Medical University of South Carolina
Phase 1/2
Recruiting
76 enrolled